Disease progression while receiving a covalent BTK inhibitor (cBTKi) defines a specific clinical scenario in chronic lymphocytic leukaemia that calls for a structured, evidence-guided change of therapy.
Patient with chronic lymphocytic leukaemia who has received a prior covalent BTK inhibitor and experienced disease progression on that therapy. TP53 status does not restrict the treatment options available in this setting.
Current guidance supports a venetoclax-based regimen — irrespective of TP53 status — as a key option in this setting, alongside other targeted approaches. The complete regimen choices, sequencing, and combination details are in the full structured protocol.